Trillium Therapeutics Inc (TSE:TRIL)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - TRIL

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - TRIL

  • Market CapCAD1.210bn
  • SymbolTSE:TRIL
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINCA89620X5064

Company Profile

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.

Latest TRIL news

Currently there for this company. Visit our news hub for other news .